^
7d
Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and Adults (clinicaltrials.gov)
P=N/A, N=1000, Not yet recruiting, Xiangya Hospital of Central South University
New trial
|
AiSuDa (ivarmacitinib)
22d
New P2 trial
|
AiSuDa (ivarmacitinib)
2ms
New P4 trial
|
AiSuDa (ivarmacitinib)
2ms
Ivarmacitinib for the Treatment of Sjögren’s Syndrome (ChiCTR2500108666)
P4, N=30, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o
New P4 trial
|
AiSuDa (ivarmacitinib)
2ms
Efficacy and Safety of Ivarmacitinib Sulfate Tablets in the Treatment of SAPHO Syndrome: A Single-Arm, Single-Center, Open-Label Clinical Trial (ChiCTR2500108339)
P4, N=20, Not yet recruiting, The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University
New P4 trial
|
AiSuDa (ivarmacitinib)
4ms
A Prospective, Multicenter Study on the Efficacy and Safety of Ivarmacitinib in the Treatment of Moderate-to-Severe Active Rheumatoid Arthritis(IMPROVE-RA) (ChiCTR2500106834)
P4, N=1000, Not yet recruiting, Nanjing DrumTower Hospital of Nanjing University Medical School; Nanjing DrumTower Hospital of Nanjing University Medical School
New P4 trial
|
CRP (C-reactive protein)
|
AiSuDa (ivarmacitinib)
4ms
JAK1 inhibitor combined with Camrelizumab as first-line therapy for PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma (ChiCTR2500106336)
P2, N=30, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
New P2 trial
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
AiRuiKa (camrelizumab) • AiSuDa (ivarmacitinib)
4ms
Efficacy and Safety of Ivarmacitinib in Patients with Polymyalgia Rheumatica: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study (ChiCTR2500105703)
P4, N=80, Not yet recruiting, The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine
New P4 trial
|
AiSuDa (ivarmacitinib)
4ms
A Multi-Center, Randomized, Controlled Trial of Ivarmacitinib in IgG4-Related Disease (ChiCTR2500105444)
P4, N=88, Not yet recruiting, Beijing Friendship Hospital Affiliated to Capital Medical University; Beijing Friendship Hospital Affiliated to Capital Medical University
New P4 trial
|
AiSuDa (ivarmacitinib)
4ms
New P2 trial • Checkpoint inhibition
|
AiSuDa (ivarmacitinib)
4ms
New P4 trial
|
PD-L1 (Programmed death ligand 1)
|
AiRuiLi (adebrelimab) • AiSuDa (ivarmacitinib)